Compare WLFC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | KURA |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1997 | 2015 |
| Metric | WLFC | KURA |
|---|---|---|
| Price | $54.28 | $12.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $160.00 | $25.56 |
| AVG Volume (30 Days) | 224.1K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $569,223,000.00 | $67,482,000.00 |
| Revenue This Year | $2.75 | $28.28 |
| Revenue Next Year | $7.35 | $106.37 |
| P/E Ratio | $22.65 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $52.13 | $7.36 |
| 52 Week High | $244.62 | $13.90 |
| Indicator | WLFC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 22.49 | 59.53 |
| Support Level | $53.40 | $8.07 |
| Resistance Level | $74.22 | $13.90 |
| Average True Range (ATR) | 2.35 | 0.74 |
| MACD | 4.36 | 0.12 |
| Stochastic Oscillator | 28.59 | 64.70 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.